Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C17H22NOS2.Cl |
| Molecular Weight | 355.946 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].COC1CC(C[N+](C)(C)C1)=C(C2=CC=CS2)C3=CC=CS3
InChI
InChIKey=QKMGSNFPZNTQHE-UHFFFAOYSA-M
InChI=1S/C17H22NOS2.ClH/c1-18(2)11-13(10-14(12-18)19-3)17(15-6-4-8-20-15)16-7-5-9-21-16;/h4-9,14H,10-12H2,1-3H3;1H/q+1;/p-1
| Molecular Formula | C17H22NOS2 |
| Molecular Weight | 320.493 |
| Charge | 1 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CNS Activity
Sources: https://en.wikipedia.org/wiki/Timepidium_bromide
Curator's Comment: Timepidium does not cross the blood–brain barrier
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898 |
34.0 nM [Ki] | ||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898 |
7.7 nM [Ki] | ||
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898 |
31.0 nM [Ki] | ||
Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898 |
18.0 nM [Ki] | ||
Target ID: CHEMBL2035 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898 |
11.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Sesden Approved UseVisceral spasms |
Doses
| Dose | Population | Adverse events |
|---|---|---|
15 mg single, intravenous Highest studied dose Dose: 15 mg Route: intravenous Route: single Dose: 15 mg Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
|
30 mg 3 times / day multiple, oral Recommended Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
Disc. AE: Eosinophilic pustular folliculitis... AEs leading to discontinuation/dose reduction: Eosinophilic pustular folliculitis Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Eosinophilic pustular folliculitis | Disc. AE | 30 mg 3 times / day multiple, oral Recommended Dose: 30 mg, 3 times / day Route: oral Route: multiple Dose: 30 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010-12 |
|
| Multiple granulomatous inflammation in the minor salivary glands: a proposed new entity, allergic granulomatous sialadenitis. | 2004-11 |
|
| Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide. | 2002 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7452982
Timepidium inhibited dose-dependently
the contraction of isolated guinea pig gallbladder evoked by stimulation at 5 Hz. The mean dose producing a 50 % decrease
in the electrically induced contraction (ID50 value) was 2.4 x 10(-8) g/ml. Timepidium (10(-6) g/ml)
also inhibited, for the most part, the contraction induced by stimulation at 30 Hz.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:54:35 GMT 2025
by
admin
on
Tue Apr 01 16:54:35 GMT 2025
|
| Record UNII |
W5689X6OZE
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
13604123
Created by
admin on Tue Apr 01 16:54:35 GMT 2025 , Edited by admin on Tue Apr 01 16:54:35 GMT 2025
|
PRIMARY | |||
|
W5689X6OZE
Created by
admin on Tue Apr 01 16:54:35 GMT 2025 , Edited by admin on Tue Apr 01 16:54:35 GMT 2025
|
PRIMARY | |||
|
100595-66-2
Created by
admin on Tue Apr 01 16:54:35 GMT 2025 , Edited by admin on Tue Apr 01 16:54:35 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |